Prince Singh1, John J Knoedler2, Amy E Krambeck2, John C Lieske1, Eric J Bergstralh3, Andrew D Rule4. 1. Department of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. 2. Department of Urology, Mayo Clinic, Rochester, Minnesota. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 4. Department of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Electronic address: rule.andrew@mayo.edu.
Abstract
PURPOSE: Thiazide diuretics used to treat hypertension are associated with a modest risk of diabetes mellitus. It is unknown if there is a similar risk with kidney stone prevention. MATERIALS AND METHODS: We identified and validated incident stone formers in Olmsted County, Minnesota from 1984 to 2011 with manual review of medical records using the Rochester Epidemiology Project. The risk of diabetes mellitus after thiazide therapy was evaluated with and without multivariate adjustment for hypertension, age, gender, race, family history of stones, body mass index and number of stone events. RESULTS: Among 2,350 incident stone formers with a median followup of 10 years, 332 (14%) were treated with thiazide diuretics at some point after the first stone event and 84 (3.6%) received the thiazide diuretic only for kidney stone prevention. Stone formers who received thiazide diuretics were more likely to be older, have hypertension, have higher body mass index and have more stone events. The incidence of diabetes mellitus at 10 years after the first stone event was 9.2% in the group that received thiazide diuretics vs 4.2% in those who did not (HR 2.91; 95% CI 2.02, 4.20). After multivariate adjustment the risk of diabetes mellitus was attenuated (HR 1.20; 95% CI 0.78, 1.83). The risk of diabetes mellitus among those receiving thiazide diuretics solely for kidney stones was further attenuated (multivariate adjusted HR 0.80; 95% CI 0.28, 2.23). CONCLUSIONS: Thiazide diuretic use for kidney stone prophylaxis was not associated with a high risk of diabetes mellitus. Larger studies are needed to determine if there is a modest risk of diabetes mellitus with thiazide diuretics.
PURPOSE:Thiazide diuretics used to treat hypertension are associated with a modest risk of diabetes mellitus. It is unknown if there is a similar risk with kidney stone prevention. MATERIALS AND METHODS: We identified and validated incident stone formers in Olmsted County, Minnesota from 1984 to 2011 with manual review of medical records using the Rochester Epidemiology Project. The risk of diabetes mellitus after thiazide therapy was evaluated with and without multivariate adjustment for hypertension, age, gender, race, family history of stones, body mass index and number of stone events. RESULTS: Among 2,350 incident stone formers with a median followup of 10 years, 332 (14%) were treated with thiazide diuretics at some point after the first stone event and 84 (3.6%) received the thiazide diuretic only for kidney stone prevention. Stone formers who received thiazide diuretics were more likely to be older, have hypertension, have higher body mass index and have more stone events. The incidence of diabetes mellitus at 10 years after the first stone event was 9.2% in the group that received thiazide diuretics vs 4.2% in those who did not (HR 2.91; 95% CI 2.02, 4.20). After multivariate adjustment the risk of diabetes mellitus was attenuated (HR 1.20; 95% CI 0.78, 1.83). The risk of diabetes mellitus among those receiving thiazide diuretics solely for kidney stones was further attenuated (multivariate adjusted HR 0.80; 95% CI 0.28, 2.23). CONCLUSIONS:Thiazide diuretic use for kidney stone prophylaxis was not associated with a high risk of diabetes mellitus. Larger studies are needed to determine if there is a modest risk of diabetes mellitus with thiazide diuretics.
Authors: Kiriaki K Stamatelou; Mildred E Francis; Camille A Jones; Leroy M Nyberg; Gary C Curhan Journal: Kidney Int Date: 2003-05 Impact factor: 10.612
Authors: Wesley O Ekeruo; Yeh Hong Tan; Matthew D Young; Philipp Dahm; Michaella E Maloney; Barbara J Mathias; David M Albala; Glenn M Preminger Journal: J Urol Date: 2004-07 Impact factor: 7.450
Authors: E Ferrannini; G Buzzigoli; R Bonadonna; M A Giorico; M Oleggini; L Graziadei; R Pedrinelli; L Brandi; S Bevilacqua Journal: N Engl J Med Date: 1987-08-06 Impact factor: 91.245
Authors: Charles Y C Pak; Khashayar Sakhaee; Orson Moe; Glenn M Preminger; John R Poindexter; Roy D Peterson; Paul Pietrow; Wesley Ekeruo Journal: Urology Date: 2003-03 Impact factor: 2.649